Andrea S. Blevins Primeau, PhD, MBA

Adding abemaciclib to adjuvant endocrine therapy improves outcomes in patients with high-risk early breast cancer, data suggest.

Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.

Lung cancer among never-smokers is the 11th most common cancer among men and the 8th most common among women, a study suggests.

In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.

Hypofractionated radiotherapy produces similar long-term outcomes as conventionally fractionated radiotherapy in high-risk prostate cancer, a phase 3 study suggests.

Prophylactic radiotherapy of asymptomatic bone metastases can reduce skeletal-related events and improve survival in patients with solid tumors, a study suggests.

Mepitel Film reduced the rate of grade 2-3 radiation dermatitis in patients with breast cancer.

Researchers sought to determine whether there would be a difference in outcomes for patients with lower-risk MDS with either a 5- or 7-day dosing schedule of azacitidine.

Patients with diverticular disease had an increased risk of lung, prostate, breast, hematologic, colorectal, gastric, liver, and pancreatic cancers.

Patients who undergo radiotherapy for the treatment of childhood cancer have an increased risk of developing meningioma later in life, and that risk may persist for 30 years.